Black individuals may be at higher risk for attention-deficit/hyperactivity disorder than the general US population.
Women are 3 times more likely to be treated for a mood disorder, depression, or anxiety than for ADHD compared with men.
A retrospective study was conducted to evaluate the demographic predictors of ADHD in hospitalized children with ASD and the impact of comorbidities on length of stay.
SHP465 mixed amphetamine salts reduced symptoms of attention-deficit/hyperactivity disorder in adults, independent of ADHD treatment history.
Investigators conducted a randomized clinical trial to assess the safety and efficacy of the investigational stimulant AR19 for the treatment of symptoms of attention-deficit/hyperactivity disorder in adults.
Having ADHD symptoms that persist into adulthood is associated with a higher risk for being involved in a motor vehicle crash.
Among adults without a clinical diagnosis of ADHD, heavy alcohol use predicted more severe ADHD symptoms.
Researchers conducted a cross-sectional study to assess nurse practitioners’ attitudes and beliefs regarding working with individuals with a mental health disorder.
In this study, researchers sought to investigate the psychometric properties of the ASRS and WURS in a well-characterized sample of adult ADHD patients and population controls.
The FDA has issued new guidance regarding the use of computerized behavioral therapy and other digital health therapeutic devices for psychiatric disorders during the coronavirus disease 2019 (COVID-19) pandemic.
Study looked at maternal serum vitamin D levels in first trimester and offspring ADHD risk.
The percentage of patients with an ADHD prescription between their 16th and 19th birthdays decreased by 19% in all patients.
Treatment should include evidence-based approaches and account for coexisting conditions.
Supplements may not improve cognitive symptoms in youth who have high endogenous EPA levels.
Researchers sought to identify the major leading nonpharmaceutical intervention for ADHD cognitive symptomology, as well as which cognitive symptoms are most amenable to change.
The New Drug Application (NDA) for viloxazine hydrochloride (SPN-812; Supernus Pharmaceuticals), a serotonin norepinephrine modulating agent, has been submitted to the Food and Drug Administration (FDA) for the treatment of pediatric patients with attention deficit hyperactivity disorder (ADHD).
Increase seen for adults of every race/ethnicity; prevalence rates highest for white individuals.
Researchers found a weak signal for persistent ADHD to be more associated with 8-year follow-up of bipolar disorder than remitting ADHD.
Recommendations include screening for comorbid conditions, understanding ADHD is chronic condition.
Significant increases in prevalence of any developmental disability and in ADHD, ASD, intellectual disability.